Adaptive Biotechnologies Corporation (ADPT)
NASDAQ: ADPT · Real-Time Price · USD
6.39
+0.39 (6.50%)
Dec 20, 2024, 4:00 PM EST - Market closed
Adaptive Biotechnologies Revenue
Adaptive Biotechnologies had revenue of $46.44M in the quarter ending September 30, 2024, with 22.46% growth. This brings the company's revenue in the last twelve months to $177.28M, down -1.34% year-over-year. In the year 2023, Adaptive Biotechnologies had annual revenue of $170.28M, down -8.11%.
Revenue (ttm)
$177.28M
Revenue Growth
-1.34%
P/S Ratio
5.28
Revenue / Employee
$250,045
Employees
709
Market Cap
943.03M
Revenue Chart
Revenue History
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
AMN Healthcare Services | 3.07B |
Aveanna Healthcare Holdings | 1.98B |
Phibro Animal Health | 1.05B |
Pacira BioSciences | 694.96M |
Liquidia | 15.61M |
ADPT News
- 10 days ago - Top 3 Health Care Stocks That May Collapse This Quarter - Benzinga
- 14 days ago - Adaptive Biotechnologies Announces New Data at the 66th ASH Annual Meeting Highlighting Advances in MRD Testing with clonoSEQ® and Its Impact on Blood Cancer Treatment Decisions - GlobeNewsWire
- 18 days ago - Adaptive Biotechnologies Announces Over 65 Abstracts Featuring clonoSEQ® MRD Testing Across a Range of Blood Cancers to be Presented at the 66th ASH Annual Meeting - GlobeNewsWire
- 25 days ago - Adaptive Biotechnologies: Making Some Progress - Seeking Alpha
- 6 weeks ago - Adaptive Biotechnologies Corporation (ADPT) Q3 2024 Earnings Call Transcript - Seeking Alpha
- 6 weeks ago - Adaptive Biotechnologies Receives Expanded Medicare Coverage of clonoSEQ® for Assessing Measurable Residual Disease in Mantle Cell Lymphoma - GlobeNewsWire
- 2 months ago - Adaptive Biotechnologies to Report Third Quarter 2024 Financial Results on November 7, 2024 - GlobeNewsWire
- 4 months ago - Adaptive Announces IVDR Certification for clonoSEQ® in European Union - GlobeNewsWire